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Abstract
Background: Current standard methods used to detect and monitor bladder cancer (BC) are invasive or have low
sensitivity. This study aimed to develop a urine methylation biomarker classifier for BC monitoring and validate this
classifier in patients in follow-up for bladder cancer (PFBC).
Methods: Voided urine samples (N = 725) from BC patients, controls, and PFBC were prospectively collected in four
centers. Finally, 626 urine samples were available for analysis. DNA was extracted from the urinary cells and bisulfite
modificated, and methylation status was analyzed using pyrosequencing. Cytology was available from a subset of
patients (N = 399). In the discovery phase, seven selected genes from the literature (CDH13, CFTR, NID2, SALL3,
TMEFF2, TWIST1, and VIM2) were studied in 111 BC and 57 control samples. This training set was used to develop
a gene classifier by logistic regression and was validated in 458 PFBC samples (173 with recurrence).
Results: A three-gene methylation classifier containing CFTR, SALL3, and TWIST1 was developed in the training set
(AUC 0.874). The classifier achieved an AUC of 0.741 in the validation series. Cytology results were available for 308
samples from the validation set. Cytology achieved AUC 0.696 whereas the classifier in this subset of patients
reached an AUC 0.768. Combining the methylation classifier with cytology results achieved an AUC 0.86 in the
validation set, with a sensitivity of 96%, a specificity of 40%, and a positive and negative predictive value of 56
and 92%, respectively.
Conclusions: The combination of the three-gene methylation classifier and cytology results has high sensitivity and
high negative predictive value in a real clinical scenario (PFBC). The proposed classifier is a useful test for predicting
BC recurrence and decrease the number of cystoscopies in the follow-up of BC patients. If only patients with a
positive combined classifier result would be cystoscopied, 36% of all cystoscopies can be prevented.
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Background
Seventy to 80% of patients with bladder cancer (BC)
present with non-muscle-invasive tumors, either con-
fined to the mucosa [stage Ta and carcinoma in situ
(CIS)] or submucosa (stage T1). Based on clinical and
pathological characteristics, non-muscle-invasive bladder
cancer (NMIBC) patients can be classified into three
different prognostic groups [1]. A minority of patients
(20–30%) have low-risk tumors with a recurrence rate of
20–30%, without progression. The second and also the
largest group, the intermediate-risk group, consists of
patients who frequently develop a non-muscle-invasive
recurrence (40–60%) but seldom progress to
muscle-invasive disease. Finally, a small group of pa-
tients has a relatively aggressive NMIBC at presentation.
The 5-year recurrence rate in this group is as high as
68% despite maximum intravesical treatment.
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Furthermore, up to 34% of these high-risk patients will
develop muscle-invasive bladder cancer (MIBC) [2]. For
this reason, an intensive follow-up schedule is
mandatory in patients with intermediate- or high-risk
NMIBC.
The follow-up schedule consists of urethrocystoscopy
and urine cytology. Depending on the patient’s risk pro-
file, the European Association of Urology guidelines rec-
ommend up to 15 urethrocystoscopies during the first
5 years of follow-up [3].
Urethrocystoscopy is considered the gold standard,
but is invasive, expensive, and moreover misses up to
15% of the papillary and up to 30% of the flat recur-
rences [4, 5]. Urine cytology, on the other hand, has a
high specificity (SP) but lacks sensitivity (SN) especially
in low-risk tumors [6]. Additionally, the interobserver
and intraobserver reproducibility of cytology is poor [7].
Recently, several non-invasive methods, NMP-22, blad-
der tumor antigen, and UroVysion FISH, have shown to
help increase the sensitivity of urine cytology. However,
due to limited specificity or sensitivity, the markers pro-
posed to date have not been widely adopted in daily clin-
ical practice. Therefore, there is a clear clinical need to
find reliable markers to monitor the recurrence in
NMIBC [8].
DNA methylation has been recognized to be import-
ant in developmental biology and cancer etiology in gen-
eral [9]. DNA methylation occurs principally at CpG
dinucleotides. These CpG dinucleotides are distributed
throughout the genome, and the majority is normally
methylated. Some regions in the genome have a high
CpG density and are called CpG islands. Hypermethyla-
tion of normally unmethylated CpG islands in the pro-
moter regions of tumor suppressor genes represses its
transcription in human tumors [9, 10]. Therefore, aber-
rant DNA methylation is a potential biomarker for diag-
nosis, prognosis, and monitoring of disease after therapy
[11]. Recently, it was shown that the combination of
SOX1, IRAK3, and L1-MET provides better resolution
than cytology and cystoscopy in the detection of early
recurrence [12]. The objective of the present study is to
investigate whether a set of methylation markers can
lead to the development of a voided urine test that pre-
dicts tumor presence and may be used to stratify BC pa-
tients according to their risk of recurrence, thus
allowing the reduction of the number of cystoscopies in
the follow-up of BC.
Methods
Patients and clinical samples
After Institutional Review Board approval and obtaining
patients’ informed consents, we prospectively collected
freshly voided urine samples from BC patients, controls,
and patients in follow-up for bladder cancer (PFBC) at
four different centers [Hospital Clínic of Barcelona
(Spain); Radboud University Medical Center in Nijmegen
(The Netherlands); St. John Emergency Hospital,
Bucharest (Romania); MD Anderson Cancer Center,
Houston, Texas, (USA)], from October 2010 to February
2012. Participating centers were asked to collect and
prepare the cell pellet by urine centrifugation and freeze
them for a final processing at the Hospital Clinic of
Barcelona or Radboud University Medical Center,
Nijmegen. We took a two-stage approach with a discovery
phase (or training set) and a validation phase (or testing
set) (Additional file 1: Figure S1). In the discovery phase,
the inclusion criteria for the cases were patients of both
sexes, 18 years of age or older, and patients with histo-
pathological confirmation of BC at any grade or stage.
Without being mandatory, we recommended patients to
have cytology at cystoscopy or during the period between
cystoscopy and surgery. Patients with a prior endovesical
chemotherapeutic or immunotherapeutic treatment could
be included. The exclusion criteria were the absence of
histological confirmation of BC and patients with other
urological malignancies (prostate, kidney, urinary tract tu-
mors). The inclusion criteria for the controls were patients
of both sexes, 18 years of age or older, and with
non-malignant urologic pathology (infection, lithiasis,
urinary incontinence, BPH) or non-urologic pathology.
The exclusion criterion for controls was a histological
confirmation of any urological malignancy.
The validation phase was designed as a cross-sectional
study including PFBC, i.e., the indicated population for
the test in daily clinical practice. For efficiency reasons,
we oversampled patients with a recurrence because we
focused on sensitivity instead of specificity (see also the
results in the “Reducing the number of follow-up cystos-
copies by using the three-gene methylation/cytology
combined classifier” section). PFBC with a prior endove-
sical chemotherapeutic or immunotherapeutic treatment
could be included. Without being mandatory, we recom-
mended PFBC to have cytology at cystoscopy. The ex-
clusion criterion was a histological confirmation of any
other urological malignancy.
A total number of 725 voided urine samples were pro-
spectively collected by the four participating institutions.
From the total number of urines collected, 99 (13%)
were excluded from the study because of technical prob-
lems during the sample collection, storage, or analysis.
Finally, 626 urines were used: 111 from BC patients and
57 from controls for the discovery phase and 458 from
PFBC (of whom 173 had a recurrence) for the validation
phase (Tables 1 and 2). The grade and stage of the tu-
mors were determined according to WHO 2004 criteria
and TNM 2002 classification, respectively [13, 14].
Tumors were classified according to their risk of re-
currence and progression into three categories: high-risk
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(HR) NMIBC (any of the following: T1, HG/G3 tumors,
or CIS), non-high-risk (nHR) NMIBC (all the other cases
of NMIBC), and muscle-invasive bladder cancer (MIBC)
(T2–4). None of the included patients had an upper
urinary tract tumor.
Urine sample processing
Urine samples were collected before cystoscopy, the day
before the transurethral resection of the bladder tumor
(TURBT), or the day before cystectomy. From all pa-
tients and controls, only one single sample was included.
For urine cytology
Urine cytology was performed according to Papanico-
laou staining and evaluated by expert pathologists in
each center blinded to the patient’s clinical history. The
results were considered as positive or negative. No cen-
tral cytology review was performed.
For methylation studies
Voided urine samples (50 to 100 ml) were collected in
sterile containers containing 4 ml of 0.5 M EDTA, pH
8.0. Urines were immediately stored at 4 °C and proc-
essed within the next 24 h. The samples were centri-
fuged at 1000×g for 10 min, at 4 °C. The cell pellets
were frozen at − 80 °C.
DNA isolation, bisulfite treatment, and PCR
DNAs from the urinary cell pellets were extracted using
QIAamp DNA Mini Kit (Qiagen) according to the
manufacturer’s instructions and quantified with a Nano-
Drop1000 (NanoDrop Technologies, Wilmington, DE,
USA). DNA extraction was performed in each center ex-
cept for Bucharest, whose cell pellets were sent in dry
ice to the Radboud University Medical Center, Nijmegen
(The Netherlands) for DNA extraction.
One microgram of genomic DNA was used for the bi-
sulfite modification using EpiTect Bisulfite kit (Qiagen,
Table 1 Clinicopathological and demographic characteristics of
the study population classified by the study phase
Discovery phase Validation phase
Training set Testing set
N bladder cancer (%) N R-PFBC (%)
Gender
Male 86 (77) 135 (78)
Female 25 (23) 38 (22)
Age
Mean 72 68
Range 39–98 26–99
Stage and grade
Tis 7 (6) 13 (8)
Ta LG 26 (23) 61 (35)
Ta HG 11 (10) 20 12)
T1 LG 20 (18) 35 (20)
T1 HG 22 (20) 44 (25)
> T2 LG 1 (1) –
> T2 HG 24 (22) –
Subtotals 111 173
N control (%)
Gender
Male 29 (51) –
Female 28 (49) –
Age
Mean 60 –
Range 22–82 –
Urinary condition
BPH 11 (19) –
Urolithiasis 13 (23) –
Incontinence 2 (4) –
Benign bladder disease 1 (2) –
Urinary tract infections 12 (21) –
Non-urological diseases 18 (32) –
Subtotals 57 –
N NR-PFBC (%)
Gender
Male – 217 (76)
Female – 68 (24)
Age
Mean – 69
Range – 26–92
Stage and grade previous TURBT
Tis – 21 (7)
Ta LG – 100 (35)
Ta HG – 53 (19)
Table 1 Clinicopathological and demographic characteristics of
the study population classified by the study phase (Continued)
Discovery phase Validation phase
Training set Testing set
T1 LG – 22 (8)
T1 HG – 82 (29)
T2 HG – 3 (1)
Tx LG – 2 (1)
Tx HG – 2 (1)
Subtotals – 285
Total 168 458
LG low-grade, HG high-grade, TURBT transurethral resection bladder tumor,
BPH benign prostate hyperplasia, CIS/Tis carcinoma in situ, BC bladder cancer,
R-PFBC recurrent patients in follow-up for bladder cancer, NR-PFBC non-
recurrent patients in follow-up for bladder cancer
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Table 2 Clinicopathological and demographic characteristics of the study population classified by the participating center
Hospital Clinic Barcelona Radboud University
Medical Center, Nijmegen
Saint John Emergency
Clinical Hospital Bucharest
MD Anderson Cancer
Center Houston
Total
Discovery phase Bladder cancer urine samples
Stage
Tis 5 – 1 1 7
Ta 14 5 5 13 37
T1 19 2 21 – 42
> T2 9 – 16 – 25
Grade
LG 20 2 17 8 47
HG 27 5 26 6 64
Subtotal 47 7 43 14 111
Control urine samples
BPH 8 3 – – 11
Urolithiasis 13 – – – 13
Incontinence 1 1 – – 2
Benign bladder
disease
4 5 1 – 10
Urinary tract
infection
1 8 4 – 13
Non-urological
diseases
6 – – 2 8
Subtotal 33 17 5 2 57
Validation phase R-PFBC URINE SAMPLES
Stage
Tis 2 1 8 2 13
Ta 13 15 47 6 81
T1 4 2 55 18 79
Grade
LG 14 8 74 – 96
HG 5 10 36 26 77
Subtotal 19 18 110 26 173
NR-PFBC urine samples
Stage previous TURBT
Tis 5 6 6 4 21
Ta 32 56 36 26 150
Ta + CIS 1 – – 2 3
T1 36 16 25 19 96
T1 + CIS 5 – – 3 8
T2 3 – – – 3
Tx 4 – – – 4
Grade previous TURBT
LG 34 35 38 19 126
HG 52 43 29 35 159
Subtotal 86 78 67 54 285
TOTAL 185 120 225 96 626
LG low-grade, HG high-grade, TURBT transurethral resection bladder tumor, BPH benign prostate hyperplasia, CIS/Tis carcinoma in situ, BC bladder
cancer, R-PFBC recurrent patients in follow-up for bladder cancer, NR-PFBC non-recurrent patients in follow-up for bladder cancer.
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Inc.) following the manufacturer’s instructions. The
modified DNA was eluted with 20 μl Tris-HCL (1 mM,
pH 8.0) and stored at − 80 °C before further processing.
Bisulfite modifications were performed in Hospital
Clinic of Barcelona, Spain (training set), and in Radboud
University Medical Center, Nijmegen, The Netherlands
(testing set).
A total of seven DNA methylation markers, i.e.,
CDH13, CFTR, NID2, SALL3, TMEFF2, TWIST1, and
VIM2, were selected from four recently published BC
studies [15–18]. The sequences of the primers used to
amplify the regions of interest of these genes and the
PCR conditions are shown in Additional file 2: Table S1.
PCR primers were designed using the PyroMark Assay
Design software v2.0 (Qiagen). PCR was performed in a
volume of 25 μl with 2 μl of converted genomic DNA,
0.6 U Ampli Taq Gold 360 DNA polymerase (Thermo-
fisher), 0.8 μl of a mix of Primer-F and biotinylated
Primer-R at 10 μM, 2 μl MgCl2 25 mM, and 0.5 μl
dNTPs 10 mM. Amplification was performed according
to the following thermocycling conditions: denaturation
at 95 °C for 10 min, followed by 45 cycles of 95 °C for
30 s, the optimal Tm for 30 s, and 72 °C for 1 min; and
a final extension at 72 °C for 7 min. The formation of
PCR products with accurate size was confirmed by
resolving PCR samples (1 μl) by 2% agarose gel elec-
trophoresis, with visualization by ethidium bromide
staining.
Pyrosequencing for quantitative methylation
Biotin-labeled single-stranded amplicons were isolated
from 20 μl of the PCR product according to the protocol
using the Pyromark Q96 Work Station and pyrose-
quenced with 0.3 μM sequence primer using PSQ96MD
System (Biotage AB). Additional file 2: Table S1 shows
the sequences of the primer sets used for bisulfite se-
quencing. The percent methylation for each of the CpGs
was calculated using PyroQ CpG Software (Qiagen). The
differences in the percentage of methylation were calcu-
lated between BC vs. control and recurrent vs.
non-recurrent PFBC (R-PFBC and NR-PFBC, respect-
ively) samples. A high correlation in the methylation
percentages of the CpG dinucleotides in the same is-
land was observed (Additional files 3 and 4: Figures
S2 and S3). For this reason, hypermethylation was an-
alyzed in all genes at the first CpG dinucleotide
present (Additional file 5: Table S2).
Data analysis
Univariable and multivariable logistic regression analyses
were used to examine the associations between BC and
DNA methylation status of urinary sediments. A forward
stepwise logistic regression was performed to determine
the best classifier between BC and control samples. The
inclusion criterion was p value of < 0.1. Risk probability
of presenting BC was calculated in the training set. We
established cutoff point value (≥ 0.464) allowing 15%
false negatives in the tumor group (SN = 85%). In the
subset of samples in which cytology results were avail-
able, the cutoff point value that yielded 85% SN in the
training set was 0.688, and in the combined model
(methylation test + cytology results), it was 0.617. If the
predicted probability value derived from each classifier
in each of the samples was higher than the cutoff point
value, the samples were classified for each of the classi-
fiers as tumor sample. The performance of the models
was evaluated in a testing set by means of AUROC using
pROC R-package [19]. Student’s t test was used to evalu-
ate statistical differences in DNA methylation. Statistical
significance was established at p value of 0.05.
R-software and SPSS v23.0 were used for calculations.
Results
Training set
DNA methylation of all seven selected genes was signifi-
cantly increased in urine sediments from BC patients
compared to controls (Fig. 1). To determine the combin-
ation of markers capable of detecting BC in urine
sediments with the highest accuracy, we built a model of
multiple markers by logistic regression. The best pos-
sible biomarker combination based on AUC was pro-
vided by the combination of CFTR, SALL3, and
TWIST1. This three-gene methylation classifier achieved
an AUC = 0.874 (Fig. 2a); at a fixed overall SN of 85%,
the classifier provides a SP of 68%. Moreover, the SN of
the three-gene methylation classifier increases through
the BC risk groups and grading (Table 3).
Testing set
To examine whether the three-gene methylation BC
diagnostic classifier was able to identify recurrences in a
clinical setting, the classifier was validated in an inde-
pendent multicenter international series of 458 urine
sediments from patients in follow-up for bladder cancer
(PFBC), of whom 173 had a recurrence. Recurrent PFBC
(R-PFBC; N = 173) displays higher percentages of DNA
methylation compared with non-recurrent PFBC
(NR-PFBC; N = 285) (Fig. 3). SN of the three-gene
methylation BC classifier increased in the validation
series (SN = 90%), while SP drops (SP = 31%), as evi-
denced by the ROC curves and AUC value (AUC =
0.741) (Table 3 and Fig. 2a). Figure 4a depicts the risk
probabilities derived from the three-gene methylation
classifier in R-PFBC and NR-PFBC.
Comparison of test performance with urine cytology
A total of 399 urine cytologies (91 from the training and
308 from the testing set) were performed. In both
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training and testing set, SN of the three-gene methyla-
tion classifier (86 and 93%, respectively) was higher than
that of the urine cytology (54 and 46%, respectively)
in this subset of samples (Additional files 6 and 7:
Table S3 and Figure S4). In the testing set, this means
that 55% of the recurrences (68 out of 124) were
detected by the three-gene classifier but were missed by
urine cytology. On the other hand, 12 recurrences were
missed by the three-gene classifier of which half was
detected by cytology (Additional file 8: Figure S5).
Negative predictive value (NPV) is also higher for the
three-gene methylation classifier than that of the urine
cytology in training (40 and 29%, respectively) and
testing set (82 and 69%, respectively). Contrary, posi-
tive predictive value (PPV) is higher for the urine cy-
tology than for the methylation classifier in training
(98 and 89%, respectively) and testing set (85 and
50%, respectively). Cytology had a SP of 93 and 94%
while the three-gene methylation classifier achieved a
SP, in this subset of samples, of 47 and 27%, in the training
and testing set, respectively. In the testing set, 120
NR-PFBC samples were positive by the three-gene
Fig. 2 ROC curves in the training and testing series for (a) the three-gene BC methylation classifier and (b) the combined three-gene
methylation/cytology classifier
Fig. 1 Percentage of DNA methylation in bladder cancer and control urine sediments for the seven selected genes analyzed in the discovery
phase. The number of samples in each group is given in brackets. Abbreviations: BC, bladder cancer; C, control
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methylation classifier. Nine of them also had positive
urine cytology (Additional file 8: Figure S5). After 1 year,
two NR-PFBC with a positive test (who had a negative cy-
tology) had a tumor recurrence.
Combination of the three-gene methylation classifier with
urine cytology
Combining the three-gene methylation classifier and
urine cytology results showed an improved diagnostic
performance in the training (AUC 0.858) and as well as
in the testing set (AUC 0.86) (Fig. 2b). A SN of 96% and
a NPV of 92% are achieved in the testing set. Of note, in
HG tumors, a 100% SN and NPV are achieved
(Additional file 6: Table S3). The risk probabilities
derived from the combined classifier in R-PFBC and
NR-PFBC are shown in Fig. 4b.
Reducing the number of follow-up cystoscopies by using
the three-gene methylation/cytology combined classifier
In our study, we oversampled patients with BC. We
therefore cannot directly calculate predictive values
from the test results. In the hospitals participating in
the study, recurrence is detected in approximately
10% of all follow-up cystoscopies performed (90% of
patients previously diagnosed with NMIBC are
without recurrence at the time of follow-up cystoscopy).
In order to calculate the predictive values that reflect
values in real clinical practice, we assumed the distribution
of recurrent vs. non-recurrent to be 10 vs. 90%. For this,
we multiplied the NR-PFBC samples by 7. Using the SN
and SP that we found in the study, the PPV and NPV in
the validation phase become 15 and 99%, respectively. If
patients with a negative classifier will not undergo a cyst-
oscopy, this means that more than a third (~ 36%) of all
cystoscopies can be prevented at the cost of 4% of recur-
rences remaining undiagnosed which all were LG tumors.
Discussion
In the present study, a set of DNA methylation markers
to predict the presence of bladder cancer (BC) in urine
samples has been selected. The best possible marker
combination to discriminate BC from controls was the
combination CFTR, SALL3, and TWIST1. We confirmed
that these genes (and specifically CpG dinucleotides
analyzed here) are hypermethylated in the bladder can-
cer tissue using methylation data from the TCGA
Research Network [20] (Additional file 9: Figure S6).
This supports their use as diagnostic markers in urine
samples. In the training set, the three-gene methylation
classifier achieved an AUC 0.874 while in the testing set,
an AUC 0.741 was achieved to discriminate recurrent
from non-recurrent patients in follow-up for bladder
cancer (PFBC). These results improved significantly in
Table 3 Diagnostic performance of the three-gene methylation
classifier in the training and testing set of samples (at fixed
sensitivity of 85% in the training set)
Training set Testing set
Overall
N samples 111 BC/57 C 173 R-PFBC/285 NR-PFBC
AUC 0.874 0.741
SN (%) 84.68 89.6
SP (%) 68.42 30.53
PPV (%) 83.93 43.91
NPV (%) 69.64 82.86
Non-high-risk NMIBC
N samples 26 BC/57 C 61 R-PFBC/285 NR-PFBC
SN (%) 73.08 88.52
SP (%) 68.42 30.53
PPV (%) 51.35 21.43
NPV (%) 84.78 92.55
High-risk NMIBC
N samples 60 BC/57 C 112 R-PFBC/285 NR-PFBC
SN (%) 86.67 90.18
SP (%) 68.42 30.53
PPV (%) 74.29 33.78
NPV (%) 82.98 88.78
MIBC
N samples 25 BC/57C –
SN (%) 92 –
SP (%) 68.42 –
PPV (%) 56.1 –
NPV (%) 95.12 –
Low-grade
N samples 47 BC/57 C 96 R-PFBC/285 NR-PFBC
SN (%) 76.6 90.62
SP (%) 68.42 30.53
PPV (%) 66.67 30.53
NPV (%) 78 90.62
High grade
N samples 64 BC/57 C 77 R-PFBC/285 NR-PFBC
SN (%) 90.62 88.31
SP (%) 68.42 30.53
PPV (%) 76.32 25.56
NPV (%) 86.67 90.62
LG low-grade, HG high-grade, AUC area under the curve, MIBC muscle-invasive
bladder cancer, NMIBC non-muscle invasive bladder cancer, NPV negative
predictive value, PPV positive predictive value, SN sensitivity, SP specificity, BC
bladder cancer, C control, R-PFBC recurrent patients in follow-up for bladder
cancer, NR-PFBC non-recurrent patients in follow-up for bladder cancer.
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the testing set when cytology results were included in
the analysis (AUC 0.86).
TWIST1 hypermethylation in BC was first described
by Renard and co-workers [16]. In a case-control study
(n = 145 cases/321 controls), they detected TWIST1 and
NID2 hypermethylation in urine sediments of BC pa-
tients using methylation-specific PCR. This two-gene
panel achieved a SN of 90%, SP of 93%, PPV of 86%,
and NPV of 95%. Nevertheless, the group of Fantony
published conflicting results. They found only a SN of
67% and SP of 69% for this two-gene urine panel
[21]. However, the results were significantly better in
the subgroup of active smokers. Unfortunately, we did
not collect information about tobacco smoking, and
therefore, we cannot perform a subset analysis for
smoking behavior.
Yu and co-workers previously found in a case-control
study that CFTR and SALL3, out of 59 genes that were
screened, were the most frequently methylated genes to
predict the presence of BC in urine [15]. However, in
this study, no PFBC were included. In daily clinical
practice, this group is especially of interest. It is not very
Fig. 3 Percentage of DNA methylation in recurrent and non-recurrent PFBC urine sediments for the three genes of the classifier in the validation
phase. The number of samples in each group is given in brackets. Abbreviations: NR-PFBC, non-recurrent patients in follow-up for bladder cancer;
R-PFBC, recurrent patients in follow-up for bladder cancer
a b
Fig. 4 Box plots showing the individual risk probabilities derived from (a) the three-gene methylation classifier and (b) the combined three-gene
methylation/cytology classifier for recurrent and non-recurrent PFBC in the cross-sectional study. Dots above the cutoff value (dashed line)
denote positive samples, whereas those below signify negatives scores. Cutoff values for the three-gene methylation classifier and the combined
three-gene methylation/cytology classifier are ≥ 0.464 and ≥ 0.617, respectively. Abbreviations: NR-PFBC, non-recurrent patients in follow-up for
bladder cancer; R-PFBC, recurrent patients in follow-up for bladder cancer
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likely that biomarkers will replace ureterocystoscopy in
patients with macroscopic hematuria referred to the ur-
ologist. But in PFBC, urinary biomarkers with a high SN
and high NPV could make a difference, i.e., lower the
number of follow-up cystoscopies. Our combined three-gene
methylation/cytology classifier achieves a high SN and NPV,
for both high-risk and non-high-risk NMIBC. Consequently,
more than a third of all cystoscopies could be prevented.
The SP of the combined classifier in the testing set,
using PFBC samples, is expected to be lower than the SP
of the training set, using BC and control samples.
Possible reasons for methylation observed in PFBC sam-
ples are small tumors not yet detected by cystoscopy, re-
sidual tumor cells at the resection site, or epigenetically
changed urothelial cells at the resection site or else in
the bladder also known as epigenetic field defect [22]. In
patients with persistent hypermethylation, which does
not recur within 18 months, the presence of an
epigenetic field defect is most likely. Wolff and
co-workers suggested that the aberrant methylation is
caused by a generalized epigenetic alteration in the
whole bladder urothelium, and this widespread methyl-
ated urothelium may be the cause of the high recurrence
rate in NMIBC [22].
The discovery of highly sensitive methylation markers
allows us to lower the number of follow-up cystoscopies
in more than a third of all follow-up patients. In the
clinical situation, patients supply a urine sample before
cystoscopy to perform the test. If the combined test is
positive, patients will undergo a cystoscopy. In our
validation series, 60% of NR-PFBC had a positive com-
bined test and should undergo a cystoscopy. This is not
a major problem since in normal daily practice,
follow-up patients would have undergone a cystoscopy
anyway. If the combined test is negative, cystoscopy
could be skipped.
However, a methylation test has also financial and lo-
gistic implications, which means that a cost-effectiveness
analysis is necessary. Using our three-gene methylation/
cytology classifier, 4% of PFBC are wrongly diagnosed as
not having a recurrence; all of them had LG NMIBC. Of
note, cystoscopy, our gold standard, misses up to 15% of
the papillary and up to 30% of the flat lesions [4].
The strengths of this study lie in the fact that we have
chosen for a two-stage approach using PFBC in the val-
idation phase. Furthermore, the use of voided urine
samples to analyze the DNA methylation status allows
the development of a non-invasive BC diagnostic tool
with an easy translation into clinical practice. However,
some limitations should be mentioned. To avoid ineffi-
ciency, patients with a recurrence were oversampled by
also recruiting patients who were scheduled for a
TURBT of a proven bladder tumor. Consequently, the
number of NR-PFBC was misrepresented in the
validation series, and we had to make an estimation to
calculate the number of cystoscopies that could be
skipped. Secondly, 13% of the samples had to be ex-
cluded due to technical failures. Thirdly, intravesical
treatments in NMIBC patients may have influenced
methylation patterns. Finally, we have evaluated only a
limited number of hypermethylated genes with diagnos-
tic value previously described in the literature.
Conclusions
In conclusion, this combined three-gene methylation/cy-
tology classifier can reduce the number of follow-up
cystoscopies in PFBC. This approach may improve the
patients’ quality of life. For a definitive conclusion, repli-
cation of the classifier in another series of patients and
cost-effectiveness studies are needed.
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Additional file 1: Figure S1. Flowchart of the entire study. A total of
seven hypermethylated genes, differentially expressed between BC patients
and controls (n= 168), were determined in the discovery phase. With these
results, a three-gene methylation classifier was developed. This three-gene
classifier was tested in a cross-sectional study (validation phase; n= 458).
Samples with available cytology results in each phase are indicated. Abbrevia-
tions: BC, bladder cancer; C, control; R-PFBC, recurrent patients in follow-up for
bladder cancer; NR-PFBC, non-recurrent patients in follow-up for bladder
cancer. (PPTX 75 kb)
Additional file 2: Table S1. Primer sequences used in PCR and
pyrosequencing. (DOCX 13 kb)
Additional file 3: Figure S2. Pearson correlation coefficient heat map
of the percentage of methylation for every CpG dinucleotide in the
seven genes. Every CpG sites are correlated (via the Pearson correlation)
with all others. Correlations are scaled by the color of the corresponding
cell. Parameters are represented in the same order on the x- and y-axes.
(PPTX 1232 kb)
Additional file 4: Figure S3. Representative pyrograms showing gene
methylation patterns in DNA urine samples from a bladder cancer
patient. Percentage of methylation is indicated above peaks (gray
columns) corresponding to the CpG sites in this region. (PPTX 183 kb)
Additional file 5: Table S2. Percentage of methylation for each CpG
dinucleotide in the seven selected genes in control and bladder cancer
urine samples. Underlined in grey the CpG site used for methylation
analysis. Abbreviations: SDV; Standard Deviation. (DOCX 21 kb)
Additional file 6: Table S3. Diagnostic performance of the three-gene
methylation classifier, cytology, and the combined methylation/cytology
classifier in the training and testing subset of samples with cytology
available. Abbreviations: LG, Low Grade; HG, High Grade; AUC, area under
curve; MIBC, muscle invasive bladder cancer; NMIBC, Non-Muscle Invasive
Bladder Cancer; NPV, Negative Predictive Value; PPV, Positive Predictive
Value; SN, Sensitivity; SP, Specificity; BC, Bladder Cancer; C, Control; R-
PFBC, Recurrent Patients in Follow up for Bladder Cancer; NR-PFBC, Non
Recurrent Patients in Follow up for Bladder Cancer. (DOCX 20 kb)
Additional file 7: Figure S4. Sensitivity, negative and positive predictive
values of urine cytology, the three-gene methylation classifier, and the
combined three-gene methylation/cytology classifier in the testing set (N =
308). Overall specificity was 94% for urine cytology, 27% for the three-gene
methylation classifier, and 40% for the combined three-gene methylation/
cytology classifier. Abbreviations: LG, low-grade; HG, high-grade; NMIBC
nHR, non-muscle-invasive bladder cancer non-high risk; NMIBC HR, non--
muscle-invasive bladder cancer high risk; NPV, negative predictive value;
PPV, positive predictive value. (PPTX 189 kb)
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Additional file 8: Figure S5. Flow diagram of participants in the
cross-sectional study according a) to the three-gene methylation classifier
and cytology results and b) to the combined three-gene methylation/cytology
classifier. Abbreviations: R-PFBC, recurrent patients in follow-up for bladder
cancer; NR-PFBC, non-recurrent patients in follow-up for bladder cancer; Cytol,
cytology; NA, non-available; Test, combined three-gene methylation/cytology
classifier. (PPTX 85 kb)
Additional file 9: Figure S6. DNA methylation profiles for bladder
cancer and control tissue samples for the three-gene classifier. Data obtained
from Wanderer Web page: http://maplab.imppc.org/wanderer/. The
red arrow indicates the CpG dinucleotide analyzed in each of the
three genes. (PPTX 203 kb)
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SP: Specificity; TURBT: Transurethral resection of the bladder tumor
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